112P - Ethnic differences in presentation of breast cancer patients treated in Hospital Kuala Lumpur, Malaysia

Date 20 December 2015
Event ESMO Asia 2015 Congress
Session Poster presentation 2
Topics Breast Cancer
Cancer Aetiology, Epidemiology, Prevention
Presenter Azura Deniel
Citation Annals of Oncology (2015) 26 (suppl_9): 16-33. 10.1093/annonc/mdv519
Authors A. Deniel1, N.A. Hakim2, N.A. Md Nordin3, T.M.I. Tg Abu Bakar Sidik4, S. Subramanian3, N.D. Kamaruzaman3, A.B. Ros Suzanna1
  • 1Radiotherapy & Oncology, General Hospital Kuala Lumpur, 50586 - Kuala Lumpur/MY
  • 2Department Of Surgery, General Hospital Kuala Lumpur, Kuala Lumpur/MY
  • 3Clinical Epidemiology Unit, National Clinical Research Centre, Kuala Lumpur/MY
  • 4Biostatistics Unit, National Clinical Research Centre, Kuala Lumpur/MY

Abstract

Aim/Background

Differences in incidence and survival between ethnic groups in South-East Asian population have been described. We attempted to explore the differences in presentation in patients diagnosed with breast cancer in Hospital Kuala Lumpur.

Methods

Using data from the hospital-based National Cancer Patient Registry in Hospital Kuala Lumpur between 2009 and 2010, a retrospective cohort study was conducted to evaluate associations between ethnicity and patients' socio-demography and clinical presentation.

Results

A total of 923 patients were identified. Ethnic breakdown comprise of Malays (58.5%), Chinese (25.2%) and Indians (12.9%). The median age at diagnosis was 53 years. A significantly higher proportion of Malays present at a younger age, with a median age of 50 years compared to Chinese (57 years) and Indians (56 years). Fifty percent of the Malays were less than 50 years at diagnosis and 6% were under 35 years. More Malays (14.2%) were diagnosed with metastatic disease at presentation, compared to Chinese (9.2%) and Indians (11.9%).

Conclusions

Results from this cohort of breast cancer patients indicate that compared to Chinese and Indians, Malays tend to present at an earlier age and more advanced stage. This echoes results that have been published earlier.

Clinical trial identification

NMRR-08-170-1325

Disclosure

All authors have declared no conflicts of interest.